Benzodiazepines carry significant risks that the NP must weigh against therapeutic benefits. Physiological dependence develops through GABA-A receptor adaptation: chronic benzodiazepine exposure causes downregulation and conformational changes in GABA-A receptors (decreased receptor density and reduced sensitivity), while simultaneously upregulating excitatory glutamate (NMDA) receptor activity as a compensatory mechanism. When the benzodiazepine is abruptly discontinued, the brain is left in a state of reduced GABAergic inhibition and enhanced glutamatergic excitation, producing withdrawal syndrome. Benzodiazepine withdrawal ranges from mild (anxiety rebound, insomnia, tremor) to life-threatening (seizures, delirium tremens-like syndrome, psychosis). Withdrawal severity depends on duration of use, dose, half-life of the agent (short-acting agents like alprazolam produce more severe withdrawal), and patient factors (elderly, hepatic impairment). The withdrawal timeline is predictable: short-acting agents (alprazolam, lorazepam) produce withdrawal within 24-48 hours of last dose; long-acting agents (diazepam, chlordiazepoxide) produce withdrawal at 3-7 days. The NP must understand tolerance development: pharmacodynamic tolerance (receptor downregulation) occurs to sedative and anxiolytic effects within 2-4 weeks, leading to dose escalation. Cross-tolerance exists with alcohol and barbiturates because all three act on the GABA-A receptor complex. This cross-tolerance...